FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:987-999 September 6, 2007 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Ezekowitz, M. D. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects. Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects.

Methods In two identical multicenter, double-blind, randomized trials, one conducted in Europe (ClinicalTrials.gov number, NCT00259428 [ClinicalTrials.gov] ) and one conducted in the United States, Canada, Australia, South Africa, and Argentina (termed the non-European trial, NCT00259376 [ClinicalTrials.gov] ), we evaluated the efficacy of dronedarone, with 828 patients receiving 400 mg of the drug twice daily and 409 patients receiving placebo. Rhythm was monitored transtelephonically on days 2, 3, and 5; at 3, 5, 7, and 10 months; during recurrence of arrhythmia; and at nine scheduled visits during a 12-month period. The primary end point was the time to the first recurrence of atrial fibrillation or flutter.

Results In the European trial, the median times to the recurrence of arrhythmia were 41 days in the placebo group and 96 days in the dronedarone group (P=0.01). The corresponding durations in the non-European trial were 59 and 158 days (P=0.002). At the recurrence of arrhythmia in the European trial, the mean (±SD) ventricular rate was 117.5±29.1 beats per minute in the placebo group and 102.3±24.7 beats per minute in the dronedarone group (P<0.001); the corresponding rates in the non-European trial were 116.6±31.9 and 104.6±27.1 beats per minute (P<0.001). Rates of pulmonary toxic effects and of thyroid and liver dysfunction were not significantly increased in the dronedarone group.

Conclusions Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia.

Source Information

From the Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA — both in Los Angeles (B.N.S.); the University of Hamilton, Hamilton, ON, Canada (S.J.C.); the University of Maastricht, Maastricht, the Netherlands (H.J.G.M.C.); the University of Montreal, Montreal (D. Roy); Lankenau Hospital and Institute of Medical Research, Philadelphia (P.R.K.); Ospedale Clinical, Taverna, Italy (A.C.); Sanofi-Aventis, Paris (D. Radzik); Hôpital Central, Nancy, France (E.M.A.); and Goethe University, Frankfurt, Germany (S.H.H.).

Address reprint requests to Dr. Singh at Veterans Affairs Greater Los Angeles Healthcare System, Cardiology Division, 11301 Wilshire Blvd., Los Angeles, CA 90073, or at bsingh{at}ucla.edu.

Full Text of this Article

Related Letters:

Dronedarone in Atrial Fibrillation
Arlet J.-B., Chouchana L., Capron L., Fink A. H. Jr., Singh B. N., Hohnloser S. H., Ezekowitz M. D.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:2403-2405, Dec 6, 2007. Correspondence

This article has been cited by other articles:

• Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., Israel, C. W., Kuck, K.-H., Lip, G. Y.H., Nattel, S., Page, R. L., Ravens, U., Schotten, U., Steinbeck, G., Vardas, P., Waldo, A., Wegscheider, K., Willems, S., Breithardt, G. (2009). Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 11: 860-885 [Full Text]  
• Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., John Camm, A., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., Israel, C. W., Kuck, K.-H., Lip, G. Y.H., Nattel, S., Page, R. L., Ravens, U., Schotten, U., Steinbeck, G., Vardas, P., Waldo, A., Wegscheider, K., Willems, S., Breithardt, G. (2009). Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 0: ehp235v1-ehp235 [Abstract] [Full Text]  
• Tejani, A. M., Yih, V., Pugliano, M., Costantino, G., Podda, G. M., Gruppo di Autoformazione Metodologica, , Horner, S. M., Floyd, J., Hohnloser, S. H., van Eickels, M., Connolly, S. J. (2009). Dronedarone in atrial fibrillation.. NEJM 360: 2479-2480 [Full Text]  
• Forleo, G. B., Tondo, C. (2009). Atrial fibrillation: cure or treat?. Ther Adv Cardiovasc Dis 3: 187-196 [Abstract]  
• Zimetbaum, P. J. (2009). Dronedarone for Atrial Fibrillation -- An Odyssey. NEJM 360: 1811-1813 [Full Text]  
• Balasubramaniam, R, Kistler, P M (2009). Atrial fibrillation in heart failure: the chicken or the egg?. Heart 95: 535-539 [Abstract] [Full Text]  
• Verma, A. (2009). Alternatives to amiodarone: search for the Holy Grail. Europace 11: 402-404 [Full Text]  
• Khoo, C. W., Lip, G. Y. H. (2009). Acute Management of Atrial Fibrillation. Chest 135: 849-859 [Abstract] [Full Text]  
• Doyle, J. F., Ho, K. M. (2009). Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis. Mayo Clin Proc. 84: 234-242 [Abstract] [Full Text]  
• Hohnloser, S. H., Crijns, H. J.G.M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., Connolly, S. J., the ATHENA Investigators, (2009). Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. NEJM 360: 668-678 [Abstract] [Full Text]  
• Coletta, A. P., Cleland, J. G.F., Cullington, D., Clark, A. L. (2008). Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur J Heart Fail 10: 917-920 [Abstract] [Full Text]  
• Camm, A. J., Reiffel, J. A. (2008). Defining endpoints in clinical trials on atrial fibrillation. Eur Heart J Suppl 10: H55-H78 [Abstract] [Full Text]  
• Dorian, P., Singh, B. N. (2008). Upstream therapies to prevent atrial fibrillation. Eur Heart J Suppl 10: H11-H31 [Abstract] [Full Text]  
• Kober, L., Torp-Pedersen, C., McMurray, J. J.V., Gotzsche, O., Levy, S., Crijns, H., Amlie, J., Carlsen, J., the Dronedarone Study Group, (2008). Increased Mortality after Dronedarone Therapy for Severe Heart Failure. NEJM 358: 2678-2687 [Abstract] [Full Text]  
• Savelieva, I., Camm, J. (2008). Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 10: 647-665 [Abstract] [Full Text]  
• Scheinman, M. M., Keung, E. (2008). The Year in Review of Clinical Cardiac Electrophysiology. J Am Coll Cardiol 51: 2075-2081 [Full Text]  
• Arlet, J.-B., Chouchana, L., Capron, L., Fink, A. H. Jr., Singh, B. N., Hohnloser, S. H., Ezekowitz, M. D. (2007). Dronedarone in Atrial Fibrillation. NEJM 357: 2403-2405 [Full Text]  
• (2007). An Amiodarone Cousin Is Modestly Effective. JWatch Emergency Med. 2007: 4-4 [Full Text]  
• Ezekowitz, M. D. (2007). Maintaining Sinus Rhythm -- Making Treatment Better Than the Disease. NEJM 357: 1039-1041 [Full Text]  
• (2007). A New Treatment for Atrial Fibrillation on the Horizon?. Journal Watch Cardiology 2007: 1-1 [Full Text]  
• Singh, B. N., Aliot, E. (2007). Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity?. Eur Heart J Suppl 9: G17-G25 [Abstract] [Full Text]